Milligan Sandra
- SEC CIK
- 0001859810
Latest role at each company
- GOSS Gossamer Bio, Inc.Directoras of Sep 25, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of May 29, 2026
- AWHL Aspira Women's Health Inc.Interim CEOas of Jan 29, 2025
- OGN Organon & Co.Head of Research & Developmentas of May 8, 2023
Trades
Every Form 4 that lists Milligan Sandra as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| GOSSGossamer Bio, Inc. | Aug 20, 2025 | Aug 19, 2025 | Milligan SandraDirector | PPurchaseCommon Stock | +26.05K | $1.92 | +$50.02K | 58.05K | +81.4% | SEC |
| GOSSGossamer Bio, Inc. | Nov 17, 2023 | Nov 15, 2023 | Milligan SandraDirector | PPurchaseCommon Stock | +32K | $0.79 | +$25.28K | 32K | New position | SEC |